Addressing Questions & Unmet Needs in Melanoma Research and Treatment
The landscape for melanoma research and treatment has rapidly changed over the last decade. Since 2011, the FDA has approved 12 new melanoma treatment regimens – including new classes of drugs that are molecularly targeted therapies (BRAF/MEK inhibitors), immune checkpoint inhibitors (anti CTLA-4, PD-1/PD-L1) and other immunotherapies (e.g. T-Vec). Scientists have also unraveled many of the genomic mutations found in the most common form, cutaneous melanoma, melanoma that arises primarily on sun-exposed areas of the skin. With these advances in research and treatment, the key unanswered questions have changed rapidly and existing preclinical models may not be sufficient to answer such questions surrounding immune checkpoint inhibition; resistance development, comparing to cuaneous melanoma, and how to improve early detection.
Importantly, there are no models that accurately predict the patient journey. New models and additional research is needed to more fully represent all melanoma subtypes, stages, or treatment responses.
Related whitepapers, case studies, etc.
Elsevier's Life Science Solutions,COVID-19 search strategies in PharmaPendium: Focus on DMPK and DDIs
17 September 2020
COVID-19 search strategies in PharmaPendium: Focus on drug safety and efficacy
10 September 2020
Text mining as a solution: Find disease-related genetic variation in literature
2 September 2020
Webinars that may also interest you
Scopus,Researchers: CiteScore 2019 and the responsible use of metrics
Hans Zijlstra (Research Metrics Product Manager) and Aileen Christensen (Senior Marketing Manager)
29 June 2020
The many helpful applications of journal impact metrics
Hans Zijlstra (Product Manager, Research Metrics) and Aileen Christensen (Senior Marketing Manager)
24 June 2020
Scopus APIs: Getting started with Scopus search
Martin Edling Andersson, Principal Product Manager and Aileen Christensen, Senior Marketing Manager
23 June 2020